Indications
Kayshild is indicated in conjunction with diet and exercise for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (fibrosis stages F2 to F3).
Composition
- Active substance
- semaglutide
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Kayshild
- Active substance
- semaglutide
- ATC code
- A10BJ06
- Therapeutic area
- Non-alcoholic Fatty Liver Disease, Liver Cirrhosis
- Marketing authorisation holder
- Novo Nordisk A/S
- Status
- Authorised